BioLineRX (BLRX)

• Market cap: $12M
• 1 day: -5.17%
• 5 days: -2.14%
• 1 month: -10.71%
• 3 months: -21.43%
• 6 months: -28.57%
• Year to date: -1.79%
• 1 year: -25.07%
• 5 years: -98.04%
• 10 years: -99.53%
• Sector: Healthcare
• Industry: Biotechnology

About: BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Employees: 28